MX2020002777A - Metodos y composiciones para tratamiento de epidermolisis ampollosa. - Google Patents

Metodos y composiciones para tratamiento de epidermolisis ampollosa.

Info

Publication number
MX2020002777A
MX2020002777A MX2020002777A MX2020002777A MX2020002777A MX 2020002777 A MX2020002777 A MX 2020002777A MX 2020002777 A MX2020002777 A MX 2020002777A MX 2020002777 A MX2020002777 A MX 2020002777A MX 2020002777 A MX2020002777 A MX 2020002777A
Authority
MX
Mexico
Prior art keywords
methods
compositions
treatment
epidermolysis bullosa
bullosa
Prior art date
Application number
MX2020002777A
Other languages
English (en)
Spanish (es)
Inventor
Evangelos V Badiavas
Original Assignee
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/712,294 external-priority patent/US20180104186A1/en
Application filed by Univ Miami filed Critical Univ Miami
Publication of MX2020002777A publication Critical patent/MX2020002777A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Physical Water Treatments (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2020002777A 2017-09-22 2018-09-21 Metodos y composiciones para tratamiento de epidermolisis ampollosa. MX2020002777A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/712,294 US20180104186A1 (en) 2013-03-13 2017-09-22 Methods and compositions for the treatment of epidermolysis bullosa
PCT/US2018/052213 WO2019060719A1 (fr) 2017-09-22 2018-09-21 Méthodes et compositions pour le traitement d'une épidermolyse bulleuse

Publications (1)

Publication Number Publication Date
MX2020002777A true MX2020002777A (es) 2020-09-17

Family

ID=65810503

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020002777A MX2020002777A (es) 2017-09-22 2018-09-21 Metodos y composiciones para tratamiento de epidermolisis ampollosa.
MX2022015753A MX2022015753A (es) 2017-09-22 2020-03-12 Metodos y composiciones para tratamiento de epidermolisis ampollosa.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022015753A MX2022015753A (es) 2017-09-22 2020-03-12 Metodos y composiciones para tratamiento de epidermolisis ampollosa.

Country Status (9)

Country Link
EP (1) EP3684336A4 (fr)
JP (1) JP7525396B2 (fr)
CN (1) CN111182890A (fr)
AU (1) AU2018335788B2 (fr)
CA (1) CA3076610A1 (fr)
EA (1) EA202090814A1 (fr)
IL (1) IL273407A (fr)
MX (2) MX2020002777A (fr)
WO (1) WO2019060719A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10640464B2 (en) 2011-01-03 2020-05-05 The William M. Yarbrough Foundation Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases
KR102125567B1 (ko) 2019-07-02 2020-06-22 한양대학교 에리카산학협력단 식물 엑소좀의 대량 생산 방법
AU2020459825A1 (en) * 2020-07-22 2023-03-16 Osaka University Therapeutic agent for dystrophic epidermolysis bullosa
KR20230074475A (ko) * 2020-08-21 2023-05-30 더 유니버시티 오브 마이애미 골수-유래 중간엽 줄기 세포로부터의 미세소포를 사용한 치료의 조성물 및 방법
EP3971440B1 (fr) 2020-09-21 2023-12-27 Brembo S.p.A. Bande de freinage d'un disque de frein à disque et disque de frein à disque
CA3228644A1 (fr) * 2021-08-12 2023-02-16 Onconova Therapeutics, Inc. Methodes et compositions pour traiter le cancer
US20230114217A1 (en) * 2021-10-12 2023-04-13 Eliksa Therapeutics, Inc. Methods of treating epidermolysis bullosa with cell-free amniotic fluid compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2972193T3 (pl) 2013-03-13 2020-08-24 University Of Miami Sposób izolacji i oczyszczania mikropącherzyków z supernatantów hodowli komórkowej i płynów biologicznych
WO2015038075A1 (fr) 2013-09-16 2015-03-19 Agency For Science, Technology And Research Procédé
US20170173113A1 (en) * 2014-03-13 2017-06-22 Research Institute At Nationwide Children's Hospital Methods of delivering heparin binding epidermal growth factor using stem cell generated exosomes
WO2016172598A1 (fr) * 2015-04-22 2016-10-27 The Broad Institute Inc. Exosomes et leurs utilisations
WO2017123022A1 (fr) 2016-01-12 2017-07-20 주식회사 강스템바이오텍 Exosome dérivé de cellules souches contenant une quantité importante de facteurs de croissance
EP3402489B1 (fr) * 2016-01-15 2021-06-09 Orbsen Therapeutics Limited Compositions d'exosomes à base de sdc2 et leurs procédés d'isolement et d'utilisation

Also Published As

Publication number Publication date
KR20200088799A (ko) 2020-07-23
CN111182890A (zh) 2020-05-19
EA202090814A1 (ru) 2020-08-07
AU2018335788A1 (en) 2020-03-19
EP3684336A1 (fr) 2020-07-29
EP3684336A4 (fr) 2021-06-02
MX2022015753A (es) 2023-01-19
WO2019060719A1 (fr) 2019-03-28
IL273407A (en) 2020-05-31
AU2018335788B2 (en) 2024-08-15
CA3076610A1 (fr) 2019-03-28
JP7525396B2 (ja) 2024-07-30
JP2020534344A (ja) 2020-11-26

Similar Documents

Publication Publication Date Title
MX2022015753A (es) Metodos y composiciones para tratamiento de epidermolisis ampollosa.
MX2018011114A (es) Métodos y composiciones relacionadas con crispr/cas para el tratamiento de beta hemoglobinopatías.
SG11202010830WA (en) Methods of treating phenylketonuria
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
IL275663A (en) Cancer treatment methods
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
MX2020001774A (es) Composiciones y métodos para tratar enfermedad colestásica.
IL268814A (en) Preparations and methods for the treatment of cancer
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
MX2020006297A (es) Variantes de cd19.
PH12017501864A1 (en) Compositions and methods for treating autism
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
IL268163A (en) Methods, compositions, and kits for treatment of cancer
IL286297A (en) Minimal residual cancer treatment methods
EP3634422A4 (fr) Méthodes de traitement de la leucodystrophie
EP3373951A4 (fr) Méthodes et compositions pour le traitement d'une épidermolyse bulleuse
IL263697A (en) Compounds, preparations and methods for the treatment and/or prevention of cancer
SG11202012055PA (en) Methods and compositions for preventing or treating calciphylaxis
SG11202010793UA (en) Methods of treating cancer
MX2020012990A (es) Formulaciones de tegavivint y compuestos relacionados.
IL276203A (en) Compounds and methods for treating cancer
IL280721A (en) A method for treating relapse of follicular lymphoma
IL277981A (en) Cancer treatment methods